Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It may rebound. But it ain't gonna rebound to $27/share! (I have a handful of pre-pre-pre reverse split shares I bought when we all thought this was a great idea. With several generic 'viagra's' due on the market this year, the universe of potential uses gets smaller all the time.
Good to see some of the long-timers still here!
Wasn't Dr. Denner a biotech whiz-kid? How is he still involved in this train wreck? Has to be a tax write-off ploy. Simply no way he ever thought this was an investment. But I bet he never ever thought it would be such a bottomless pit of failure.
I've been away after selling out over two years ago at a great loss. The only accomplishment Pascoe has under his belt is this: he has been paid handsomely for years of worthless 'successes.' Every deal he and the board made screwed the company. The 'Room Temperature Device'- the classic Pascoe Fiasco.
I feel everyone's pain this morning. Been there, done that.
Pascoe is disappointed? Weren't APRI's scientific staff in constant talks with the FDA? Knowing that a prior application was denied, one would think APRI's preparation for this try would have been irrefutable. How come it wasn't? That was the ONLY job the entire staff had to work on.
Either the FDA was misleading APRI so they supplied inferior or incomplete data, or APRI didn't understand what they had to do or knowingly supplied incomplete or inferior data because full data wouldn't support their claim. Which do you think is more likely?
I think when a management team manages to destroy tens of millions of stockholder equity, time and time again, it's time to close the company and return any leftover funds to the shareholders.
But Pascoe won't do this- his ego as CEO won't let him. He enjoys his salary and perks as every one of us lost their shirts.
How he always got re-elected is beyond me.
Haven't been in for a while. Seems to me that Pascoe sold cheap- considering that Ferring got the entire planet except for the USA. Will the FDA actually give approval in our lifetime? Will Pascoe and ilk get the damn application in front of the FDA in the '3rd qtr?'
He has a wonderful track record of not meeting his own goals. The sale gives the company some cash for a while. Will it be wasted on executive bonuses? Let me be very serious about this. My 'investment' has dwindled every time Pascoe has put his hand on the rudder of this company. I'm sure many of you are in the same boat. Pascoe still makes his half-million dollar a year salary. I know departmental managers that have bigger budgets, oversee hundreds of employees, and make one quarter of what WE give the guy.
When Denner came on board, we all thought this train would finally make it to the station. I imagine Denner will somehow take a 'special dividend' from this money trying to repair what must be his biggest disappointment, not to mention his biggest loss.
What happens when Ferring puts some muscle and talent behind Vitaros, 'perfects' the stinking RTD and starts to make real money? I'll tell you- they take all of it for themselves. As THEIR train pulls into the station, we'll be watching. I think Ferring played some real hardball and Pascoe knew he was beaten.
I hope it spikes like heck in the morning- but it won't stay there. The shorts will be right back in like sharks on a seal. Good luck to all.
Anything around here is still a take-under. I'd rather they take a final shot at FDA approval. With many thousands of scripts filled in Europe over the past 2 years, there must be a body of evidence from the EU's 'FDA' that the FDA can draw upon to allow a fast-path to a PDUFA date.
But I'm not complaining- if it gets back to it's price when it reverse-split, I'll be happy. Still climbing after hours....
Could Pascoe have pulled a deal out of his hat? Or gotten some sort of positive regulatory news? We can hope!
What the heck's happening? Trump say he uses the stuff?
First, IR is paid (somehow) by the company using company supplied info. They will never give us anything useful. Second, if a $4.00 two chamber tube of epoxy can keep the ingredients separate until use, and then mix the stuff until it's the perfect mixture for immediate use, I can't fathom the issues the company is having. They must have their night cleaner doing the design work. Third, the entire Board Of Derelicts should resign for they have proven beyond a shadow of doubt that they don't give a tinker's damn about this company, other than as a source of income. The board should have reduced Pascoe's salary to $50,000 a year. They have no balls to do what is needed. I hope the FDA gives Vitaros a nod and lets it through without too much hassle. But even if that does pass, the fiasco in Europe proves Pascoe can't manage the company.
Obviously, a degree in 'Leadership' may be useful to a drill instructor or platoon leader, but it's clear as day that it doesn't mean sh-t when it comes to running a company. Just my 2 cents.
hey folks- what's going on? real news? 2 million shares by 11:15?
Biotechs in general getting hit hard today, so seeing this company with its warts getting clobbered isn't too surprising. The real question is where is it going to find a bottom?
Price is just collapsing. I had high hopes for this company. But board member after board member leaving is not good- for all sorts of reasons. Two members removed for shady dealings? The one big-time member who could give credibility resigns since he doesn't want to be part of anything questionable. Where there's smoke......
Which leads me to question the CEO's integrity and all the company-sponsored "research." That too may end up in the toilet.
The newest (and oldest) board member just resigned.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On June 20, 2016, William D. Smithburg resigned as a member of the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”), effective immediately. In connection with his resignation, Mr. Smithburg referred to the article by Bleecker Street Research, published by Seeking Alpha on June 20, 2016, entitled “Pershing Gold And ChromaDex Exposed: These Barry Honig Names Could Fall 70-80% (Or More)” (the “Bleecker Report”). Mr. Smithburg indicated that while he had no reason to believe that there was any truth to the statements in the Bleecker Report regarding the Company, he had determined that at this stage of his life he was unable to be involved as a Board member in any company that was the subject of a malicious attack of this nature, but that he did intend to continue to support the Company and its management as an investor. According to the Form 3 filed by Mr. Smithburg on June 14, 2016, Mr. Smithburg owns 640,000 shares of Company common stock.
I thought he already was!
The CEOs of Enron, Worldcom and plenty others that went into the toilet said the very same thing as investigators closed in. Just sayin'.....
The CEO still hasn't explained how he got Dunkerley on board- or how he vetted him. Still hasn't come clean on the conversation of how Dunkerley got fired or resigned after his SEC investigation became public.
Sort of like Nixon proclaiming, "I am not a crook!" while his henchmen did all the illegal stuff. Right now, all we've heard from the company is "I am not a crook." Time for some honest and transparent answers.
Buying a few thousand shares is window dressing. Let's see them mortgage their house and buy a hundred thousand shares if this is such a great price- and if the company goes to zero, so do they. I don't think the former will happen, while the latter may.
Hi folks- I'm new to this board. Anyone have any ideas why the stock is spiking afterhours (right now)? Thanks Dave
I totally understand your point- and in other circumstances I'd agree with you. But the board invited Dunkerley to join them- they HAD to have known what this guy was up to and who he was hanging with. I find it hard to believe that the BoD, who have a fiduciary responsibility to the shareholders, allowed Dunkerley to join the board. All the other items need to be fleshed out and see what in heck is really going on.
The Board SHOULD have told us exactly why Dunkerley abruptly left (resigned or fired) AND how they 'misjudged' the guy in the first place. Instead, we need to read about his SEC charges in the press. Hiding dirty laundry is never the right thing to do. The only question here is whether or not this is a miniature Enron, where the entire company was crooked, or a Tyco, where just the execs were thieves. Either case, I'm on the side for now.
This wasn't just guys with a few thousand shares bailing out. These were bigger positions. I think the old adage, "Where there's smoke, there's fire," may be appropriate here.
Guilt by association may also come into play. There's no way to undo the damage of the Dunkerley fiasco. The players mentioned all have histories that would make a loan shark envious. The simple fact that Dunkerley was put on the board shows the true colors of the company. Do you think any company of any integrity would ever put such a guy on their board? Of course not- no decent company would ever take the chance.
I wouldn't be surprised if the single study that showed some benefit is now suspect. I wouldn't put anything past these guys.
Oh boy, the company is formulating a reply.
Either the entire article is a lie or CDXC is on very thin ice. Since it doesn't take hours or days figure out how to say "The whole story is a lie," I have to think that the company is designing a reply that won't get them in hotter water for issuing false statements. No matter how you slice it, it ain't gonna taste good.
Too many cronies with past pump-and-dump histories. The science MAY (and I do mean 'may') be real, but there's not enough of it. Not going to take the chance that this goes to fifty cents. I'm out. Good luck everyone! (I think that's the same line everyone said on the Titanic...)
Thanks. We just have to 'stay-tuned' and see what happens. At least the company like to put out press releases often.
Here's the kind of info that's confidential. The asterisk-in-brackets in the actual document displays in this post as a bullet and replaces the name or type of product P&G are considering.
2.1.
PROJECT. The PARTIES will collaborate on the project, including key milestones and success criteria, set forth in Schedule 2.1 (“PROJECT”), which is expected to result in the development of STABLE NR and/or PRODUCTs intended for application in the COLLABORATION FIELD. The PARTIES may amend Schedule 2.1 by mutual agreement from time to time pursuant to Paragraph 11.4 (Entire Agreement / Amendment).
2.1.1.
Summary of the PROJECT. The PROJECT generally relates to the identification and use of STABLE NR in P&G’s consumer products for the .
and
6.3.
Purchase Requirements. In the event a) sampling in Paragraph 6.1 (Sampling) and Paragraph 6.2 (Sampling Inventions) results in any creative idea, design development, invention, know-how, or work result (whether patentable or not patentable); b) there is no commercial agreement between the PARTIES for the purchase of NR or STABLE NR by P&G from COLLABORATION PARTNER; and c) if P&G launches a product containing NR or STABLE NR within 2 years from the date of Termination of this JDA; P&G will purchase its requirements for NR for use either by itself or in the preparation of STABLE NR in connection with from COLLABORATION PARTNER at COLLABORATION PARTNER’S MFN PRICING for a period of or 3 years from the date of the first retail sale of any such PRODUCT.
Here's the link to the doc: https://www.sec.gov/Archives/edgar/data/1386570/000141588916005140/cdxc_ex10-44.htm
As far as I can tell, our company is just protecting itself and doesn't want to spill-the-beans on some product that others might create on their own. P&G can safely work on this new or improved existing product without competitors looking over their shoulders.
I think the company is on the level and is working diligently to build itself into something greater. If the next drug trial provides validating evidence of the efficacy of the Niagen, then we're off to the races. With the possibly crooked board member removed, the company wants to present itself as the real deal- not a pump-and-dump or a 'rest-home' for mediocre board members. On dips, I'm accumulating again.
Much ado about nothing. The withheld information is just about a possible P&G product that may use a CDXC ingredient.
Then what is so 'top secret' that they won't tell the people who own the company?!
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
June 7, 2016
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ChromaDex Corp.
File No. 0-53290 - CF #33625
_____________________
ChromaDex Corp. submitted an application under Rule 24b-2 requesting
confidential treatment for information it excluded from the Exhibits to a Form 10-K on
March 17, 2016.
Based on representations by ChromaDex Corp. that this information qualifies as
confidential commercial or financial information under the Freedom of Information Act,
5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly
disclose it. Accordingly, excluded information from the following exhibit will not be
released to the public for the time period specified:
Exhibit 10.44 through October 30, 2020
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Brent J. Fields
Secretary
Really? Is this the name of the owner of all those new shares? Why doesn't he want his name revealed? Or maybe some financial mess that Dunkerley did and Jack is just sweeping it under the carpet for the next 4 years?
Hi gang. I'm new to this board. I have a question: Is the Hugh Dunkerley who recently abruptly resigned the same Hugh Dunkerley mentioned in this SEC investigation?
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 13, 2016, Hugh Dunkerley, a member of the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company”), resigned from the Board and as a member of the compensation committee of the Board (the “Compensation Committee”). Mr. Dunkerley’s resignation was not the result of any disagreements with the Company’s operations, policies, or practices. As a result of his departure from the Board, Mr. Dunkerley will no longer be standing for re-election to the Board at the Company’s Annual Meeting of Shareholders on June 2, 2016.
And the SEC investigation:
Devon Archer, Jason Galanis and others face securities-fraud charges related to alleged tribal bond scheme
By
CHRISTOPHER M. MATTHEWS
Updated May 11, 2016 8:08 p.m. ET
Federal prosecutors charged a former campaign adviser to Secretary of State John Kerryand a second man once dubbed by the media “porn’s new king” along with five others in an alleged scheme involving a Native American Tribal bond offering.
Devon Archer, an adviser to Mr. Kerry’s presidential campaign in 2004, and Jason Galanis, a former investor in the adult-entertainment business, allegedly duped clients into investing more than $43 million in sham bonds issued in 2014 and 2015 by an affiliate of the Oglala Sioux Nation in South Dakota.
Messrs Archer, Galanis and the five other defendants, including Mr. Galanis’s father, then allegedly diverted tens of millions of the bond investments to accounts they controlled and used them to purchase luxury goods and support an initial public offering for a technology company, authorities said.
Lawyers for Mr. Archer and for Mr. Galanis and his father didn’t immediately respond to requests for comment.
All seven defendants were arrested Wednesday, and the Manhattan U.S. attorney’s office charged them with securities fraud. The Securities and Exchange Commission filed related civil charges.
Along with Jason Galanis, 45 years old, those arrested were his father, John Galanis; Devon Archer; Bevan Cooney; Hugh Dunkerley; Gary Hirst and Michelle Morton.
Susan Brune, a lawyer representing Mr. Dunkerley, said her client “looks forward to addressing the charges.”
Did the BoD ASK Dunkerley to leave and let him 'save face?' Is there any chance of Dunkerley's financial games have been played on CDXC shareholders?
Hi guys- I haven't been watching this since Bulldog Tech folded. What's going on? Is the company real or is some pump-and-dumper just getting a shell ready for some scam? Thanks-
Who owns the 20 million broker non-votes? You mean to tell me there people who have this in street name and don't fill out the proxy? 20 million???
That they've just given up on it and don't give a crap about it anymore?
With these do-nothing non-votes, Denner effectively controls the company. I'm not sure if that's a good or bad thing right now.
I did enjoy seeing almost 2 million 'votes withheld' from Kleanthisxanthopolisthermopolisacropolis and Rusty- it means at least some of us are showing our disappointment. (As if our company actually cared!)
Have a great holiday weekend folks!
Any of you folks see the replay of the Japan Airlines (JAL) CEO who took a paycut down to 90K a year a decade ago? Seems his multibillion dollar company was having a rough time and he wanted to show everyone that he was doing everything in his power to fix things.
JAL, thousands of employees, billion dollar company, and CEO takes home 90K a year. He takes the bus to work. Eats in the employee cafeteria.
Now look at our guy, the man who pretends he's a Fortune 500 CEO. Makes over half a million dollars a year, plus perks, and accomplishes nothing. Accepts hundreds of thousands of options without the slightest feeling of revulsion for being rewarded for a job done terribly.
To paraphrase a past president: "Don't ask what your company can do for you, ask what you can do for your company."
Pascoe and ilk (BoD) have mismanaged so many aspects of this company that they should be cover material for Forbes "Worst CEO of the Year" issue.
By ANY standard, stock price, cash preservation, dilution, job performance, etc., they all STINK. I would gladly accept the entire boards' resignation and bring in a bunch of 70 year old big pharma retirees to do their jobs.
Pascoe, for not having the decency to refuse the stock awards ("I neither earned nor deserve them.") should be fired for cause. He's squandered the company's money and hasn't shown the slightest urgency to get the RayVa study completed at the earliest possible time. He's deadwood collecting a paycheck. For half his salary, we can go get a Harvard/Stanford/MIT PhD-MBA willing to move mountains to get a crack at leading a biotech. WE SHOULD LOOK INTO THIS.
Or do we just sit and watch our 'investment' go to zero?
And Denner is silent? Did he just give up?
I guess this pretty much proves that most of Denner's prior results were of the 'rising tide lifts all boats' kind. You can get away with that for only so long- and then the market eats you alive. It's almost funny, trying to figure out what Pascoe's 'Plan B' is. (As if he knows.)
With the remaining cash, complete the RayVa study asap. How hard could this be? It's a topical cream that either works or it doesn't. Slather it on, wait 30 minutes, take an infra-red picture. Done. Either the colors show increased blood flow or they don't. We don't need to wait 6 months or longer for that. (Of course, Pascoe would, he collects a freakin' jackpot everytime he gets paid- he'd want to drag this out as long as possible, since he will never get a real job again in this business.)
I've owned small biotechs before this, but this one has to go down as my singular worst selection in 45 years of investing. How in hell isn't it possible to perfect this 'room-temperature-device in the last three years?
You could crowd-source the design and have a prototype in 48 hours if they really wanted to. I think the only desire this board has is to collect a paycheck, nothing more. The folks that sold Fem to us must be acting like the used car salesman that finally unloaded the clunker for a great price. Oh well, let's see how this plays out. It's just entertainment value from here on out. "It's the Pascoe & Clowns Biotech Parade of Excuses Show!"...
As SB said, "As for APRI, the free shares at these levels to "retain" the team that took the company to a $30 million market cap tells you all you need to know."
I agree completely. If ANYONE one the board had any integrity, they would have said, "No equity grants or options until share price is above $1.50. We must show the owners of the company that we are good stewards of their investment." The execs are lucky their salaries weren't cut in half. As it is, Pascoe will will still make over half a million dollars for pretty much an abysmal performance. But the annual meeting is around the corner. Hope you vote appropriately on the proxy.
We should kick out the entire board. Our 'boys club' for the old and feeble has run its course. No reason to think they can improve upon their past performance, and lord knows we've given them every chance.
I think Bassam Damaj must be having a good laugh. He probably recommended Pascoe knowing that he'd take the company back to the pink sheets.
Well, I guess we've all learned that IBD's 8% stop should be etched in stone, right?
At this point, we've all accepted that this money is either dead or close to it, and we've decided to let it play out and see what happens. Here's hoping for the best, fellas!
Last thing: any officer of this company talking about 'retention awards' should be fired. The people who draw a salary at this company are very well paid and the thought of having to BRIBE them to stay, especially after this year's performance, is repugnant. If they want to leave, let them. Offer that BRIBE to some new people.
As the update stated about RayVa: "and partner ex-U.S. prior to initiating any future clinical studies."
So either there isn't any money to pursue this on their own or they don't really believe in it. I mean, really, how much could a P2B or P3 cost to monitor 50 or 500 people glopping some goo over their hands over the course of several weeks?
The glacial speed with which Pascoe has pushed RayVa may be telling us more than we want to know... Meanwhile, VVUS has been skyrocketing for no apparent reason. With its now lofty price, it could buy APRI for stock and not blink an eye. (But only after Denner cleans house. No need to bring all that baggage with him.)
VVUS, another Denner-involved company has been very strong recently. Maybe inflating the stock for a takeover (or under) of APRI to get the Vitaros rights in the US? Denner could drop almost every APRI exec and employee and let VVUS staff handle everything. APRI personnel expenses drop to insignificant numbers and VVUS has the alternative to Viagra in its tool chest. Almost makes sense.
I wonder what excuse the useless BoD will use when they decide to reprice the just repriced options?
"Due to market conditions, we find it useful to retain high-performance executives by lowering the exercise price of all outstanding option grants to twenty-five cents. This will ensure the high-performance executives are well-compensated for their effective leadership and dedication to increasing shareholder value.
As an addendum, 'the bar' which is usually raised to measure strong performers has been lowered so that even a mouse with two broken legs could get over it.
Pascoe's new measurements of achievement will include:
- parking in his assigned space without touching the lines
- able to open the door to his office building by himself
- able to answer his telephone without assistance
- able to negotiate the cafeteria without help
- turning the lights on in the office
- being able to turn on his computer by himself
- being able to name the company he works for without using notes
- and other criteria that the BoD may decide as indicative of superior leadership ability
"
What was the name of the company that sold F to us? Boy did they make the deal of the century! Now we know why THEY didn't run with it. They knew something...
APRI makes 'The Gang that Couldn't Shoot Straight' look like high achievers!
As Pascoe said, "“We are obviously disappointed with these results,” said Richard Pascoe, Chief Executive Officer of Apricus. “As a consequence of these results, we will discontinue all development of fispemifene in symptomatic secondary hypogonadism, and focus our resources on our other homegrown pipeline assets. Specifically, we will focus on growing ex-U.S. Vitaros® revenues, seeking U.S. Vitaros approval in 2017, and advancing RayVa™ with a Phase 2 clinical development program. We believe that focusing on these higher return assets, along with streamlining the organization and reducing our operating expenses, is in the best interest of shareholders.”
Looks like a couple of the recently hired folks will be giving up their parking passes. Maybe, just maybe, 'in the best interests of the organization,' Pascoe will reduce his operating expense! It would be nice to hear him say, "I'll work for $50,000 a year until RayVa is commercialized." But I don't think his ego will let him do that.
Par for the APRI course. I think the stock awards, even though they'll never be exercised, should be taken back. (If any of the recipients had any dignity, they'd give them back, including Pascoe's raise!) Somebody's 'science' wasn't thoroughly researched and the P1 and P2A studies must be suspect. In any case, in micro-bios, drugs fail all the time. but this still hurt. Let's how the RayVa studies shape up. (But I'm not holding my breath for statistically significant results.) And to think that APRI paid millions of dollars for the right to this failure.
Let's all be civil to each other. If the announcement is positive, we'll all be happy, some very happy. If it's not, so be it. It's been a very long ride for many of us and even if the news is fantastic, we may only approach break-even. For all those who had the balls to go in at the recent historic lows, congratulations!
Maybe Denner and Pascoe will actually earn their rewards. But in my book, repricing everything to pennies was a slap in the face to every shareholder and simply didn't need to be done.
Fingers crossed for good news!
I agree with SB, every word. Pascoe, as far as I can tell from his actions, is a carpetbagger. He hasn't proved himself to be a capable steward of the company. And yet OUR pathetic board awards him for doing the most mediocre job I've seen in years. One would think that tossing hundreds of thousands stock options at execs just prior to releasing drug trial results would be seen as insider trading. For the life of me, 'fiduciary' is not a word our board or CEO seems to know the definition of.
The next question is why such a huge grant of options? Why a pay raise? WHAT has he done to merit this largess? I have a great suggestion for the BOD: Tell the shareholders exactly how Pascoe "exceeded expectations!" If he DID, then your 'expectations' list must have had the bar set very LOW.
Most companies set 'the bar' higher every year. APRI wins the "Lowest Expectations for CEO" award, AGAIN!!! The BoD is truly a disappointing bunch of has-beens. APRI seems to be the place where the dead wood from other companies finds a cozy home.
By EVERY metric, the company is floundering. Denner is trying to figure out how to salvage his reputation, nothing more. I'm sure the funds that own positions in this are very concerned.
Heck, after F results are in and not 'statistically significant," we'll hear Pascoe spin the results and then the Bod will REPRICE every stinking award to about thirty-five CENTS. And you know what? Pascoe will be able to take a 5 year vacation with what we've paid him over these 3 years and then some other about-to-fail company will take him on. If Pascoe ran a division in any major pharma company, instead of being 'king' of this one, and had to answer to another manager, he'd have been booted out for non-performance. And that's the simple truth.
The RayVa study should have been totally completed months ago. The glacial pace of this study is just another clue as to how well the company is run. Other than that, have a nice afternoon.
Just taking this to its logical conclusion, what if the Fem study is a flop? What if Vitaros starts making peckers fall off? What if Rayva starts growing extra fingers? Will Pascoe re-price the warrants to say, 5 cents? Maybe 1 cent? Will our fiduciarily-impaired BoD hand out option grants with an exercise price of 1 cent????
I'm surprised The Onion hasn't spotlighted our grand little company's antics. "Board of Directors decide shareholders don't matter!" or how about, "Apricus Bioscience: a company whose Board never passes on handouts to themselves!"
Yup, we got a board that would make the folks at Tyco, Enron, and Global Crossing proud. (If they weren't all dead or in prison, that is.)
I guess we can only hope that Fem is a roaring success and RayVa does help people in the next phase of the trials. Just seems unfair that our company management has handed out stock option grants, tens of thousands of them, with an exercise price of 97 cents, when just about every shareholder in existence has a cost basis of 2, 3, 4, and even 5 and 6 times that price. Isn't it nice to know that they look after themselves first?
And we can't even vote them out anymore!
If Pascoe and the BOD would like to do something for the shareholders, (since they seem to be impaired when it comes to growing the share price), they can issue the same warrants to the existing shareholders- so that we all may participate if the price ever moves up.
Hey SB, I agree with you on all of it. I swear that Pascoe, had he been old enough to serve, would have gotten fragged in Nam for such behavior. Maybe the new motto of 'The Point' is something like, "Screw the troops, I'm an officer!"
I know that the officers of my father's outfit in WWII were honorable men who would put themselves in harm's way before putting their men there.
Recall that Santarus popped almost 40% when Salix took them over. Of course, Santarus had revenue from good products already, but it was their new UC drug that made them so attractive. Today's news is good, no doubt about it, but we need to get to the next stage, which looks like it will take a year.
if Dolcanatide works out in later phase trials, this will be a $30+ stock. UC is a scourge that seems to be unstoppable, so the more weapons we have against it, the better.
The real question is whether or not another company wants to buy them on the cheap before Dolcanatide wraps up Ph2. I'm sure other companies have this company on their radar.
You know, I was just informed by one of the largest health insurers in the country that they won't be covering Viagra in 2016. I checked around and the true cost (no insurance) of a stinking Viagra pill is around $45! Cialis is a little more than half that price.
Insurers are balking at paying for Viagra due to its price, which Pfizer just raised, so there's going to be a huge need to be filled. This would be Pascoe's 'opportune moment' the get Vitaros moving in this country. What in heck is he waiting for?
I don't give Pascoe high marks for integrity or transparency, which is a blot on his West Point education, which you and I paid for through our taxes.
At this point, I hope to get out even. Denner has shown that not everything he touches turns to gold. I hope I'm wrong. I hope the RayVa and Fem show great results. I hope the RTD is the greatest thing since sliced bread- but it has taken longer to build this simple device than it took the Manhattan Project to invent and build the atomic bomb.
Isn't it amazing that our executives think they worth such lofty salaries? Their gluttony is simply amazing to behold.
I hate to throw a wet towel on this party, but even with the bump on Friday, we have to remember that the board decided to make a quorum of only 33% vote of the outstanding shares to make a decision. That effectively gives Denner and friends control of the company. We can go along for the ride but will have no further control of any kind over what happens to the company. I find it very hard to believe that any court (at least in the USA) would find that making a quorum of only a 33% vote of the outstanding shares was in the best interests of the stockholders. The Board has a fiduciary responsibility to all the shareholders, not just the big holders. Why would any board pull something like this? I can only imagine the SEC alarms that went off when this was submitted. I'm sure the company is now on some 'watch list' for insider trading.